Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736411 | 0.86 | GRM5 (0.39) | GRM5OPRM1SIGMAR1KCNJ1NPY5R | |
| SCHEMBL3742257 | 0.82 | GRM5 (0.37) | GRM5KCNJ1NPY5RADRA1AKCNH2 | |
| SCHEMBL3748343 | 0.82 | GRM5 (0.37) | GRM5KCNJ1NPY5RADRA1AKCNH2 | |
| SCHEMBL3741302 | 0.81 | HSD11B1 (0.42) | GRM5NPY5R | |
| SCHEMBL3741297 | 0.81 | HSD11B1 (0.42) | GRM5NPY5R | |
| SCHEMBL3747817 | 0.81 | HSD11B1 (0.42) | GRM5OPRM1SIGMAR1KCNJ1NPY5R | |
| SCHEMBL3747815 | 0.81 | HSD11B1 (0.42) | GRM5OPRM1SIGMAR1KCNJ1NPY5R | |
| SCHEMBL13045560 | 0.76 | HSD11B1 (0.47) | KCNJ1NPY5RADRA1AKCNH2 | |
| SCHEMBL13079376 | 0.73 | GRM5 (0.62) | GRM5NPY5RADRA1AKCNH2 | |
| SCHEMBL4022146 | 0.72 | NPY5R (0.53) | GRM5OPRM1SIGMAR1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | GRM5 25/4885OPRM1 183/4885SIGMAR1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.